达沙替尼治疗儿童慢性粒细胞白血病的进展分析
Analysis of the Progress of Dasatinib in the Treatment of Chronic Myeloid Leukemia in Children
DOI: 10.12677/ACM.2021.1112918, PDF,   
作者: 覃 欢, 于 洁*：重庆医科大学附属儿童医院血液肿瘤科，国家儿童健康与疾病临床医学研究中心，儿童发育疾病研究教育部重点实验室，重庆
关键词: 慢性粒细胞白血病；儿童；达沙替尼；Chronic Myeloid Leukemia； Children； Dasatinib
摘要: 慢性粒细胞白血病(Chronic Myeloid Leukemia, CML)是一种恶性肿瘤性疾病。该病在儿童中罕见，治疗多参考成人经验。目前有几种酪氨酸激酶抑制剂已被批准用于治疗儿童CML。达沙替尼治疗儿童慢性粒细胞性白血病是有效的，但其报道少，本文总结其在儿童CML中的疗效及安全性等。
Abstract: Chronic Myeloid Leukemia is a malignant tumor disease. It is rare in children, requiring extrapolation from the treatment of adults. Several tyrosine kinase inhibitors (TKIs) are approved for the treatment of children’s CML. Pediatric CML is effectively treated with long-term targeted therapy using dasatinib, but there are few reports, in this review, we summarize its efficacy and safety in children’s CML.
文章引用：覃欢, 于洁. 达沙替尼治疗儿童慢性粒细胞白血病的进展分析[J]. 临床医学进展, 2021, 11(12): 6189-6194. https://doi.org/10.12677/ACM.2021.1112918

参考文献

[1] Hochhaus, A., Saussele, S., Rosti, G., et al. (2017) Chronic Myeloid Leukaemia: ESMO Clinical Practice Guidelines for Diagnosis, Treatment and Follow-Up. Annals of Oncology, 28, v41-v51. [Google Scholar] [CrossRef] [PubMed]
[2] Hochhaus, A., Baccarani, M., Silver, R.T., et al. (2020) European LeukemiaNet 2020 Recommendations for Treating Chronic Myeloid Leukemia. Leukemia, 34, 966-984. [Google Scholar] [CrossRef] [PubMed]
[3] Bansal, D. (2020) Chronic Myeloid Leukemia in Children: Challenges and Opportunities. The Indian Journal of Pediatrics, 87, 443-450. [Google Scholar] [CrossRef] [PubMed]
[4] Andolina, J.R., Burke, M.J., Hijiya, N., et al. (2019) Practice Patterns of Physician Treatment for Pediatric Chronic Myelogenous Leukemia. Biology of Blood and Marrow Transplantation, 25, 321-327. [Google Scholar] [CrossRef] [PubMed]
[5] Hijiya, N., Schultz, K.R., Metzler, M., et al. (2016) Pediatric Chronic Myeloid Leukemia Is a Unique Disease That Requires a Different Approach. Blood, 127, 392-399. [Google Scholar] [CrossRef] [PubMed]
[6] Champagne, M.A., Capdeville, R., Krailo, M., et al. (2004) Imatinib Mesylate (STI571) for Treatment of Children with Philadelphia Chromosome-Positive Leukemia: Results from a Children’s Oncology Group Phase 1 Study. Blood, 104, 2655-2660. [Google Scholar] [CrossRef] [PubMed]
[7] Gore, L., Kearns, P.R., de Martino, M.L., et al. (2018) Dasatinib in Pediatric Patients with Chronic Myeloid Leukemia in Chronic Phase: Results from a Phase II Trial. Journal of Clinical Oncology, 36, 1330-1338. [Google Scholar] [CrossRef] 
[8] Keating, G.M. (2017) Dasatinib: A Review in Chronic Myeloid Leukaemia and Ph+ Acute Lymphoblastic Leukaemia. Drugs, 77, 85-96. [Google Scholar] [CrossRef] [PubMed]
[9] Levêque, D., Becker, G., Bilger, K., et al. (2020) Clinical Pharmacokinetics and Pharmacodynamics of Dasatinib. Clinical Pharmacokinetics, 59, 849-856. [Google Scholar] [CrossRef] [PubMed]
[10] O’hare, T., Walters, D.K., Stoffregen, E.P., et al. (2005) In Vitro Activity of Bcr-Abl Inhibitors AMN107 and BMS-354825 against Clinically Relevant Imatinib-Resistant Abl Kinase Domain Mutants. Cancer Research, 65, 4500-4505. [Google Scholar] [CrossRef] 
[11] Lombardo, L.J., Lee, F.Y., Chen, P., et al. (2004) Discovery of N-(2-chloro-6-methyl-phenyl)-2-(6-(4-(2-hydroxye- thyl)-piperazin-1-yl)-2-methylpyrimidin-4-ylamino)thiazole-5-carboxamide (BMS-354825), a Dual Src/Abl Kinase Inhibitor with Potent Antitumor Activity in Preclinical Assays. Journal of Medicinal Chemistry, 47, 6658-6661. [Google Scholar] [CrossRef] [PubMed]
[12] Zwaan, C.M., Rizzari, C., Mechinaud, F., et al. (2013) Dasatinib in Children and Adolescents with Relapsed or Refractory Leukemia: Results of the CA180-018 Phase I Dose-Escalation Study of the Innovative Therapies for Children with Cancer Consortium. Journal of Clinical Oncology, 31, 2460-2468. [Google Scholar] [CrossRef] 
[13] Christopher, L.J., Cui, D., Wu, C., et al. (2008) Metabolism and Disposition of Dasatinib after Oral Administration to Humans. Drug Metabolism & Disposition, 36, 1357-1364. [Google Scholar] [CrossRef] [PubMed]
[14] Aplenc, R., Blaney, S.M., Strauss, L.C., et al. (2011) Pediatric Phase I Trial and Pharmacokinetic Study of Dasatinib: A Report from the Children’s Oncology Group Phase I Consortium. Journal of Clinical Oncology, 29, 839-844. [Google Scholar] [CrossRef] 
[15] Vaidhyanathan, S., Wang, X., Crison, J., et al. (2019) Bioequivalence Comparison of Pediatric Dasatinib Formulations and Elucidation of Absorption Mechanisms through Integrated PBPK Modeling. Journal of Pharmaceutical Sciences, 108, 741-749. [Google Scholar] [CrossRef] [PubMed]
[16] Mccafferty, E.H., Dhillon, S. and Deeks, E.D. (2018) Dasatinib: A Review in Pediatric Chronic Myeloid Leukemia. Pediatric Drugs, 20, 593-600. [Google Scholar] [CrossRef] [PubMed]
[17] Shah, N.P., Kantarjian, H.M., Kim, D.W., et al. (2008) Intermittent Target Inhibition with Dasatinib 100 mg Once Daily Preserves Efficacy and Improves Tolerability in Imatinib-Resistant and -Intolerant Chronic-Phase Chronic Myeloid Leukemia. Journal of Clinical Oncology, 26, 3204-3212. [Google Scholar] [CrossRef] 
[18] Deininger, M.W., Shah, N.P., Altman, J.K., et al. (2020) Chronic Myeloid Leukemia, Version 2.2021, NCCN Clinical Practice Guidelines in Oncology. Journal of the National Comprehensive Cancer Network, 18, 1385-1415. [Google Scholar] [CrossRef] [PubMed]
[19] Scalzulli, E., Caocci, G., Efficace, F., et al. (2021) Real-Life Comparison of Nilotinib versus Dasatinib as Second-Line Therapy in Chronic Phase Chronic Myeloid Leukemia Patients. Annals of Hematology, 100, 1213-1219. [Google Scholar] [CrossRef] [PubMed]
[20] Markovic, U., Bulla, A., Leotta, S., et al. (2020) Second-Line Dasatinib Therapy Improved Compliance and Deep Molecular Responses in Imatinib-Intolerant Chronic Myeloid Leukemia Patients. Anticancer Research, 40, 5313-5317. [Google Scholar] [CrossRef] [PubMed]
[21] Chen, L., Yuan, G., Zhong, Z., et al. (2018) Efficacy and Safety of Generic Dasatinib as a Second-Line Treatment for Patients with Chronic Myeloid Leukemia: A Multicenter Retrospective Study in Hubei Province, China. Current Medical Science, 38, 1005-1011. [Google Scholar] [CrossRef] [PubMed]
[22] Ono, T. (2021) Which Tyrosine Kinase Inhibitors Should Be Selected as the First-Line Treatment for Chronic Myelogenous Leukemia in Chronic Phase? Cancers, 13, 5116. [Google Scholar] [CrossRef] [PubMed]
[23] 杨森, 秦亚溱, 赖悦云, 等. 慢性髓性白血病患者达沙替尼相关的肺部不良反应分析[J]. 中华血液学杂志, 2020, 41(12): 1013-1019.
[24] Naqvi, K., Jabbour, E., Skinner, J., et al. (2019) Long-Term Follow-Up of Lower Dose Dasatinib (50 mg Daily) as Frontline Therapy in Newly Diagnosed Chronic-Phase Chronic Myeloid Leukemia. Cancer, 126, 67-75. [Google Scholar] [CrossRef] [PubMed]
[25] 中华医学会血液学分会. 慢性髓性白血病中国诊断与治疗指南(2020年版) [J]. 中华血液学杂志, 2020, 41(5): 353-364.
[26] Chen, Y., Zou, J., Cheng, F., et al. (2021) Treatment-Free Remission in Chronic Myeloid Leukemia and New Approaches by Targeting Leukemia Stem Cells. Frontiers in Oncology, 11, Article ID: 769730. [Google Scholar] [CrossRef] [PubMed]
[27] Saikia, T. (2018) The Cure of Chronic Myeloid Leukemia: Are We There Yet? Current Oncology Reports, 20, 12. [Google Scholar] [CrossRef] [PubMed]
[28] 朱晓健, 游泳, 段明辉, 等. 慢性髓性白血病患者酪氨酸激酶抑制剂自动停药的多中心回顾性研究[J]. 中华血液学杂志, 2018, 39(12): 994-997.
[29] Rea, D., Nicolini, F.E., Tulliez, M., et al. (2017) Discontinuation of Dasatinib or Nilotinib in Chronic Myeloid Leukemia: Interim Analysis of the STOP 2G-TKI Study. Blood, 129, 846-854. [Google Scholar] [CrossRef] [PubMed]
[30] Liu, Y., Shao, Z., Liao, Y., et al. (2020) Targeting SKP2/Bcr-Abl Pathway with Diosmetin Suppresses Chronic Myeloid Leukemia Proliferation. European Journal of Pharmacology, 883, Article ID: 173366. [Google Scholar] [CrossRef] [PubMed]
[31] Braun, T.P., Eide, C.A. and Druker, B.J. (2020) Response and Resistance to BCR-ABL1-Targeted Therapies. Cancer Cell, 37, 530-542. [Google Scholar] [CrossRef] [PubMed]

为你推荐